PTCB Pharmacist Intervention, Event Reporting and Infection Control study guide

What this topic actually asks of you

Domain 3 of the PTCE is Patient Safety and Quality Assurance (23.75%). The other three of its six knowledge areas sit here:

Issues that require pharmacist intervention (e.g., drug utilization review [DUR], adverse drug event [ADE], OTC recommendation, therapeutic substitution, misuse, adherence, post-immunization delivery care, allergies, drug interactions)

That is KA 3.3, and it carries the outline's calculation footnote;

Event reporting procedures (e.g., medication errors, adverse effects, product integrity, MedWatch, VAERS, near miss, root-cause analysis [RCA], continuous quality improvement [CQI])

KA 3.4; and

Infection prevention procedures and cleaning standards (e.g., handwashing, personal protective equipment [PPE], cleaning counting trays, countertops, and equipment)

KA 3.6. Together they are the knowledge areas about the technician's boundary and the machinery on either side of it: when a problem is handed to the pharmacist, who an event is reported to, and what keeps a pharmacy from spreading an infection.

There is one line in this topic, and every scenario is a version of it. A pharmacy technician recognizes a problem, gathers the information, flags it, and refers it — and a pharmacist resolves it. That is true of a drug-interaction alert, an out-of-range dose, an adverse event, a suspicious prescription and a patient who looks unwell. A question that has the technician deciding is a question with the wrong answer, and the wrong answers are usually phrased as competence: "the technician recognizes the interaction and changes the drug", "the technician counsels the patient on the side effect".

The boundary is the state board's, not federal law's. Federal law does not set technician scope — it sets what a pharmacy may do and how controlled substances move. A technician's authority to perform a given task comes from the state board of pharmacy, and in practice from the employer's policy on top of it. The federal programs guide frames the same split from the federal side, and the two should be read together.

Reporting is a routing question, and routing is memorizable. A drug problem, a vaccine problem and a device problem go to three different places, and only some of them are forms a consumer can file. The sections below end in a table for exactly that reason.

Compounding is where this topic gets technical. USP's chapters are the standards a compounding pharmacy is measured against, and they are freely accessible at usp.org/compounding. This guide teaches the structure and the vocabulary — which chapter governs what, what the categories mean, what a PEC is.

The scope line, as scenarios

DUR alerts: what they are and who resolves them

Drug utilization review (DUR) is the structured, ongoing review of how drugs are used. CMS describes the Medicaid program this way: "Medicaid DUR is a structured, ongoing program that interprets patterns of drug use … and includes prospective drug review, retrospective drug use review, data assessment of drug use against predetermined standards, and ongoing educational outreach activities." The statutory basis is section 1927(g) of the Social Security Act, which since 1993 has required each state to run a DUR program, and the program has two halves:

• Prospective DUR — review before the claim pays, by an electronic screening system. CMS lists what the screen looks for: potential and actual adverse effects; therapeutic duplication; drug-disease interactions and contraindications; incorrect dosage, frequency or duration; drug allergy; clinical misuse or abuse; drug-drug interactions; medication appropriateness; overuse and underuse of therapy; and pregnancy alerts.
• Retrospective DUR — review of claims data after the fact, to find patterns: therapeutic appropriateness, adverse events, use of generic products, incorrect duration, inappropriate or medically unnecessary care, gross overuse, abuse and fraud.

Which alerts may a technician override? This is the exam's version of the scope line: none clinically. A DUR alert is a flag, and every category in that list is a clinical judgment. The technician's role is to make sure the flag reaches the pharmacist with the information attached — the allergy list, the other medications, the patient's own report — and never to clear it.

Counseling and an OTC question

A patient asks "can I take this with my blood pressure pills?", or wants an OTC recommendation, or wants to know what a side effect means. All three are counseling, and counseling is the pharmacist's. The technician's part is real and worth naming: listen, gather the facts (what else they take, what the doctor said), get the pharmacist, and hand the conversation over rather than guessing.

The outline puts "OTC recommendation" in the same knowledge area as DUR, and the reason is that an OTC recommendation is a clinical decision about a drug: the fact that no prescription is involved changes nothing.

A suspected adverse drug event

An adverse drug event (ADE) is harm from a drug, whether or not an error caused it. When a patient says "I started that new pill and now I'm dizzy", that is a clinical judgment about a drug: the pharmacist decides whether the drug is responsible, whether it should stop, and whether the prescriber must be called. The technician does not assess the reaction and does not tell the patient to keep taking it or to stop; the technician gets the pharmacist and, if the patient is in distress, gets help immediately.

The same rule covers the post-immunization question — a patient who has just been vaccinated and does not feel right, or who asks what to expect — and any question about adherence that is really a question about therapy.

A suspected fraud or an altered prescription

A prescription that has been altered (a changed quantity, a changed refill count, a different drug written over), a forged signature, a patient using several pharmacies, or a doctor-shopping pattern is a pharmacist's problem — and, if confirmed, a legal one. The technician's job is the opposite of confrontation: do not accuse, do not fill it yourself — the pharmacist decides that, and do not hand the prescription back with an explanation. Gather what is in front of you, keep the document, and get the pharmacist quietly. The controlled-substance half of this — the forgery red flags and the corresponding-responsibility duty — belongs to the controlled substances guide.

Therapeutic substitution against generic substitution

Two substitutions, and the difference is the whole question:

• A generic substitution replaces a brand with an equivalent generic of the same drug — same active ingredient, same strength, same dosage form. That is what a pharmacy does routinely, under state law and formulary rules.
• A therapeutic substitution replaces the drug with a different drug in the same class — one statin for another, one proton-pump inhibitor for another. That is a new therapy, so it is the pharmacist's decision, made together with the prescriber.

The technician can do the first and never the second. "The class is the same" is exactly the reasoning that makes the error, which is why it appears in this guide's "pairs to keep apart".

The patient who looks unwell

A patient who is short of breath at the counter, unsteady, confused, having chest pain, or who says they took too much of something is not a pharmacy problem at all — it is an emergency. The action is: get the pharmacist, and call emergency services if the patient cannot wait. Do not counsel, do not sell anything, do not send them home to "see how it goes". This scenario is in the bank because it tests whether the rule is memorized as refer rather than as handle it.

What the technician can do

Everything above is a "no" — so it is worth being explicit that the technician's role here is substantive, not passive. The technician can:

• Gather information — the allergy history, the other medications, the insurance, the patient's own description of what happened.
• Record it in the profile, so the pharmacist has it.
• Flag it: put the alert, the note or the prescription in front of the pharmacist.
• Refer the patient, and keep the queue moving while the pharmacist resolves the clinical question.

That is the whole shape: recognize, gather, flag, refer. A scenario question that offers a technician action will offer one of those four as the right answer, and a clinical resolution as the trap.

Reporting an event

MedWatch: Form 3500, Form 3500B and Form 3500A

MedWatch is the FDA's program for reporting serious problems with human medical products. FDA describes what it receives as "serious reactions, product quality problems, therapeutic inequivalence/failure, and product use errors", and the reporting is voluntary for health professionals and the public: FDA's own page says plainly that "FDA relies on the voluntary reporting of these events", and that "Your health care provider is NOT required to report to the FDA." Three forms carry the program, and who files each is the question:

So the split is not by event but by reporter: the same serious reaction is a voluntary 3500 when a pharmacist reports it and a mandatory 3500A when the manufacturer does.

VAERS: a vaccine adverse event

VAERS is the Vaccine Adverse Event Reporting System, and it is co-sponsored by the CDC and the FDA. FDA's page states who reports:

• Anyone can report an adverse event to VAERS — the system accepts reports from the public.
• Health care professionals are required by law to report any adverse event listed in the VAERS Table of Reportable Events Following Vaccination that occurs within the time period specified for that event, and any event the vaccine's manufacturer lists as a contraindication to further doses.
• Vaccine manufacturers must report all adverse events that come to their attention.
• Health professionals are strongly encouraged to report anything else clinically important — including vaccine administration errors — even when it is not clear the vaccine caused it.

The exam's trap here is the direction of the requirement: the provider has a legal duty only for the table events and the contraindication events, while the manufacturer must report everything it hears about. And a vaccination error — the wrong vaccine, the wrong dose — is reportable to VAERS even with no harm.

A device problem: MedWatch and MAUDE

A device problem is not the same as a drug problem, and the names matter:

• MedWatch still receives device reports from health professionals and consumers, and
• MAUDE — the Manufacturer and User Facility Device Experience database — is where the FDA's device adverse event data lands: FDA states it "contains medical device reports (MDRs) of adverse events", keeps the last ten years of them, and updates monthly. The mandatory reporters are manufacturers, importers and device user facilities; a user facility reports device-related deaths to both the FDA and the manufacturer, and serious injuries to the manufacturer (or to the FDA if the manufacturer is unknown), while importers report deaths, serious injuries and malfunctions.

So for a device: the report path is MedWatch → FDA, the database everyone reads afterward is MAUDE, and "user facility" is a legal category (a hospital, an outpatient treatment facility, a nursing home) with its own duty.

ISMP's reporting program

ISMP runs the ISMP Medication Errors Reporting Program (ISMP MERP) — ISMP describes it as "the only national voluntary practitioner medication error reporting program". It is the place a near miss goes: an error that was caught, and that no form requires anyone to report, but that another pharmacy can learn from. It is voluntary and confidential, and NCC MERP's severity index (see the high-alert medications guide) is implemented in its database, which is what makes the reports comparable.

The internal incident report

The internal incident report is the pharmacy's own record of what happened — and the fact the exam tests is what it is not: an incident report is not part of the patient's medical record. It is a quality-improvement document, written to fix the system rather than to document care, which is also why it is kept separate from the chart and handled under the organization's own confidentiality rules.

Two more facts about it: the purpose is system improvement, not blame (the "just culture" position), and it is written regardless of harm — a near miss that was caught before the bag left the counter is exactly what an incident report is for.

VICP, at concept level

The National Vaccine Injury Compensation Program (VICP) is the no-fault alternative to the traditional legal system for vaccine injury claims, and HRSA runs the program. The pieces worth knowing:

• It was created in the 1980s after lawsuits threatened vaccine supply and vaccination rates.
• Any individual of any age who received a covered vaccine and believes they were injured may file a petition; parents, legal guardians and legal representatives may file on behalf of children, disabled adults and people who are deceased.
• The petition is filed with the U.S. Court of Federal Claims, not with a pharmacy or the FDA. HHS medical staff review it, the Department of Justice writes the report, and a court-appointed special master decides whether compensation is awarded.
• The program is driven by the Vaccine Injury Table, which lists the injuries and the timeframes associated with each covered vaccine (HRSA's current table is the version revised and effective January 3, 2022).

At concept level, that is the whole answer: no-fault, a table decides what qualifies, and it is a court process — which is why it is not one of the forms a pharmacy files.

Which system for which event

Continuous quality improvement

Continuous quality improvement (CQI) is the loop that makes the reports above worth collecting: measure, find the pattern, change the process, measure again. The outline names CQI inside KA 3.4, beside event reporting — because a report that changes nothing is just paperwork. Two consequences for a technician:

• The same error twice is a system finding, not two careless people.
• CQI is where RCA and FMEA land. A root cause analysis (after an event) and a failure mode and effects analysis (before one) are the two tools; CQI is the habit of acting on what they find. The high-alert medications guide covers both.

Infection control and cleaning

Hand hygiene: hand rub against soap and water

Hand hygiene is the single most effective infection-control act in healthcare, and the CDC's rule is narrower than most people assume. CDC's guidance is that an alcohol-based hand sanitizer (ABHS) is preferred over soap and water in most clinical situations — unless hands are visibly soiled — "because it is more effective at killing germs on hands than soap, is easier to use when providing care … results in improved skin condition with less irritation and dryness than soap and water, and improves hand hygiene adherence."

Soap and water is required, not preferred, in four situations the CDC lists:

• when hands are visibly soiled;
• before eating;
• after using the restroom;
• during the care of patients with suspected or confirmed infection during outbreaks of C. difficile and norovirus.

That last one is the exam's favorite, and the reason is mechanical: alcohol does not reliably kill C. difficile spores, and friction-and-water rinsing is what removes them. So the rule is not "soap is better" — it is "for spores and for soil, you need the physical removal alcohol cannot do".

When hands must be cleaned (the CDC's list, verbatim): immediately before touching a patient; before performing an aseptic task such as placing an indwelling device or handling invasive medical devices; before moving from a soiled body site to a clean body site on the same patient; after touching a patient or the patient's surroundings; after contact with blood, body fluids or contaminated surfaces; and immediately after glove removal.

Standard precautions and PPE

Standard precautions are the infection-control practices applied to every patient, every time — because you cannot tell who is infectious from looking. CDC's core-practices document states that its core practices "should be implemented in all settings where healthcare is delivered", naming inpatient and outpatient settings and, explicitly, pharmacies, and the practices are the same set used across healthcare: hand hygiene, use of personal protective equipment (PPE) when contact with blood, body fluids, secretions or excretions is anticipated, injection and medication safety, environmental cleaning and disinfection of surfaces and equipment, and occupational health for the staff (immunization, staying home when ill, and OSHA standards including the Bloodborne Pathogens standard).

PPE basics, and what each item is for:

• Gloves — for contact with blood, body fluids, non-intact skin and mucous membranes, and for handling hazardous drugs or contaminated items. Gloves are not a substitute for hand hygiene: they are removed and hands are cleaned after removal, which is why "immediately after glove removal" is on the CDC's list.
• Gown — when soiling of clothing or skin is anticipated.
• Mask, eye protection and face shield — when splashes or sprays could reach the face (this is also the hazardous-drug PPE logic under USP <800>).
• Dedicated or single-use equipment where shared equipment can carry organisms between patients.

For a technician the practical version is: clean hands before and after every task, glove for the contacts that warrant it, and treat every counter and tray as contaminated. The sharps half of this — the OSHA bloodborne-pathogens rules and needle disposal — is in the administration, equipment and supplies guide and the federal programs guide's hazardous-waste section.

Counting trays, equipment and cleaning

The outline names the pharmacy's own equipment: "cleaning counting trays, countertops, and equipment". The rules a technician is expected to know:

• Clean the counting tray between drugs — the tray and spatula are the pharmacy's shared surface, and residue from one drug in the next patient's bottle is a cross-contamination and an allergy risk.
• Use a dedicated or specially cleaned tray and spatula for hazardous drugs, and for the allergens a pharmacy flags (penicillin, sulfa), under the organization's policy. The hazardous-drug handling rules — dedicated equipment, PPE, deactivation and decontamination — come from USP <800>, below.
• Return-to-stock and will-call checks: an unclaimed prescription that never left the counter may return to stock after verification and a claim reversal; a prescription a patient has taken home may not — once it is in a patient's possession it is out of the pharmacy's control, the same rule the returns counter follows in the NDC, lot and expiration guide.
• Label placement and bag checks at the point of sale, which are the last human check before the medication reaches the patient.

Compounding standards

USP <795>: nonsterile compounding

USP's compounding chapters are the standards a compounding pharmacy is measured against, and the three that matter here divide by the kind of preparation:

• USP <795> — nonsterile preparations: creams, ointments, oral suspensions, capsules, and anything compounded that never has to be sterile.
• USP <797> — sterile preparations: anything that will be injected or infused — injections and infusions, irrigations for internal body cavities, ophthalmics, aqueous inhalations and implants, among other sterile routes.
• USP <800> — hazardous drugs: how hazardous drugs are handled by anyone who touches them, in compounding and everywhere else.

<795> and <797> were revised, and the revisions are what the exam reflects: the earlier low-risk / medium-risk / high-risk terminology is gone, replaced by a category framework (for <797>, Categories 1, 2 and 3), and the beyond-use-date rules were rebuilt around those categories.

What <795> governs, at the level its structure makes clear:

• Who may compound, and in what conditions — designated space, surfaces, equipment, and the cleanliness of both.
• The two records every nonsterile preparation carries: the master formulation record, which is the recipe (ingredients, quantities, equipment, instructions, BUD and packaging), and the compounding record, which is what was actually made, by whom, when, and from which lot numbers.
• The equipment — mortar and pestle, spatulas, an ointment slab, graduates, and a balance — and the techniques that go with them, below.
• Default beyond-use dates when the master formulation record does not set its own: a preserved aqueous preparation keeps 35 days (controlled room temperature or refrigerated), a nonpreserved aqueous preparation keeps 14 days refrigerated, a nonaqueous oral liquid keeps 90 days, and other nonaqueous dosage forms keep 180 days.

USP <797>: sterile compounding

Sterile compounding is where contamination is invisible, so <797> is built around where the work happens and how long the product may be kept:

• Category 1, 2 and 3 CSPs. Every compounded sterile preparation is assigned a category, and the category sets its default beyond-use date and how strictly it must be handled. A preparation assigned a shorter, stricter category cannot simply be re-labeled with a longer one.
  • Category 1 is the least strict: a beyond-use date of ≤ 12 hours at controlled room temperature, or ≤ 24 hours when refrigerated, and it may be prepared in a PEC in an unclassified segregated compounding area (SCA) — no cleanroom suite required.
  • Category 2 needs the cleanroom suite: the PEC inside an ISO Class 7 buffer room, entered from an ISO Class 8 ante-room.
  • Category 3 is Category 2 plus additional quality-assurance requirements.
• Immediate-use CSPs. A narrow carve-out for a preparation made and given within a very short window, without the full sterile-environment chain — the exception that proves the rule, and a favorite question stem. The rule is a clock: administration must begin within 4 hours of the start of preparation.
• The facility, in ISO classes. For a Category 2 or 3 preparation, the work happens inside a primary engineering control (PEC) whose air is ISO Class 5 (the cleanest), which sits in a buffer area at ISO Class 7, entered from an ante-room at ISO Class 8. A Category 1 PEC may sit in an unclassified SCA instead — the ISO 7 / ISO 8 suite belongs to Categories 2 and 3. The classes describe particle counts in the air, and the number gets larger as you move away from the drug.
• The PECs, by name: a laminar airflow workbench (LAFW), a biological safety cabinet (BSC), and the compounding aseptic isolators — CAI (compounding aseptic isolator) and CACI (compounding aseptic containment isolator). Which one a pharmacy needs follows from whether the drug is hazardous.
• Aseptic technique: the concepts are first air (the air that reaches the critical site first, before it has crossed anything else, so nothing is placed between the filter and the opening), critical sites (the sterile openings — vial septa, syringe tips, needle hubs), keeping hands and work well back from the airflow's edge, and disinfecting stoppers with sterile 70% isopropyl alcohol.
• Garbing. The exact order of donning and doffing every item is set by the facility and documented in its SOP — USP does not fix one universal sequence. The invariants a question can turn on: garb runs from the dirtiest item to the cleanest; outer garments and jewelry come off first; hand hygiene comes before gowning; and sterile gloves go on last, in the buffer area. Nothing that touched the floor or the outside of the pharmacy is put on after a sterile item.
• Personnel qualification and monitoring — gloved fingertip sampling and media-fill tests to qualify a person, and environmental monitoring of the air and surfaces to qualify the room.

USP <800>: hazardous drugs

<800> answers a different question from <797>: not how clean is the product, but who is exposed while it is handled — the technician, the pharmacist, the patient, the housekeeper. Its structure:

• Who must comply: every entity that handles hazardous drugs, and everyone who handles them, in every setting — not only sterile compounding.
• Which drugs are hazardous: the current NIOSH list is the basis. The edition that applies now is the 2024 List of Hazardous Drugs in Healthcare Settings (NIOSH Publication No. 2025-103, December 2024), which "supersedes the NIOSH List of Antineoplastic and Other Hazardous Drugs in Healthcare Settings, 2016" and reorganized the drugs into Table 1 (drugs with manufacturer's special handling information and/or an NTP/IARC carcinogen classification) and Table 2 (drugs meeting the NIOSH definition without that handling information). The 2016 three-way grouping — antineoplastic, other non-antineoplastic, and reproductive risk — is the older structure and no longer the list's organization; the reproductive-risk flag survives inside Table 2. Check the edition before quoting a group, and say "the current NIOSH list" when the point is that the list exists, not which edition it is.
• The Assessment of Risk: an entity may decide that a specific dosage form on the NIOSH list does not need full containment, but only through a documented, reviewed assessment of risk — not a blanket exemption, and not a decision taken once and filed away.
• Receiving and storage: unpack hazardous drugs where the air is controlled for the purpose, and store them apart from other inventory, in the conditions the chapter sets. The point is containment — of aerosols and of spills.
• PPE: the chapter specifies the gloves, gown and other protection for handling HDs, and its gloves are the ones tested to an ASTM standard for chemotherapy penetration rather than ordinary exam gloves.
• Containment while compounding: the work happens in a containment PEC inside a containment secondary engineering control (a C-PEC within a C-SEC), for the same reason a hazardous drug is not compounded in an open room.
• A defined order of cleaning: deactivation (chemically neutralizing the drug), then decontamination, then cleaning, then disinfection. The order is worth memorizing, because doing them in a different order spreads the drug rather than removing it.
• Closed-system drug-transfer devices (CSTDs), spill kits and waste handling — the mechanical half of containment. The waste half cross-refers to the federal programs guide's hazardous-waste section.

The compounding techniques

Five techniques, and the exam tests them as definitions:

• Trituration — reducing a solid to fine particles by rubbing it in a mortar and pestle.
• Levigation — reducing particle size by mixing a powder with a liquid (a levigating agent) to form a paste, so the powder stops flying and the grit disappears.
• Geometric dilution — mixing a small amount of a potent drug with an equal volume of diluent, then adding an equal volume again, and again, until the batch is uniform. It is how a tiny quantity of potent drug is spread evenly instead of sitting as a speck in a jar.
• Spatulation — mixing, usually a powder with a base, with a spatula on an ointment slab rather than by grinding.
• Pulverization by intervention — making a hard, gummy or otherwise un-grindable solid workable by adding a solvent, grinding it, and letting the solvent evaporate.

Numbers, forms and lists to know

Pairs to keep apart

How to practice this

• Read the free pharmacist intervention and infection control practice set and, on each item, find the verb: if the right answer is recognize, gather, flag or refer, it is a technician answer; if it is decide, counsel, change or override, it belongs to the pharmacist.
• Memorize the routing table, not the prose: drug → MedWatch; vaccine → VAERS; device → MedWatch/MAUDE; near miss → ISMP MERP; internal → incident report; money claim → VICP.
• Fix the hand-hygiene exception in one sentence: alcohol by default; soap and water for spores, soil, food and the restroom.
• Learn the garbing invariants — dirtiest first, sterile gloves last, the rest is the facility's SOP — and the cleaning order as deactivate → decontaminate → clean → disinfect.
• Work the high-alert medications guide for the NCC MERP index the near-miss reports are sorted by, and the federal programs guide for the waste and sharps rules.

Where to go next

• Next topic — pharmacy calculations
• The exam itself — the passing score, how many questions, and what makes the PTCB exam hard.

This topic sits inside Domain 3 — Patient Safety and Quality Assurance, 23.75% of the exam — the outline's own weight, and PTCB publishes no per-knowledge-area split.

PTCE® is a registered trademark of the Pharmacy Technician Certification Board (PTCB). Elk Ridge Academy is not affiliated with or endorsed by PTCB.